Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare [0.03%]
医保环境下在弥漫大B细胞淋巴瘤中成本效益模型分析转换为生物仿制药美罗华联合化疗(CHOP)方案
Joshua A Roth,David Kratochvil,Kathryn Perkins et al.
Joshua A Roth et al.
Background: Rituximab-pvvr (Ruxience), -abbs (Truxima), and -arrx (Riabni) are biologic therapies approved by the United States Food and Drug Administration (FDA) as biosimilars to originator rituximab (Rituxan). Each is ...
The economic burden of moderate-to-severe rheumatoid arthritis in Spain: the CIARA study [0.03%]
西班牙风湿性关节炎的经济负担：CIARA研究
Lucía Silva-Fernández,Alejandro Balsa Criado,Raimon Sanmartí et al.
Lucía Silva-Fernández et al.
Aims: The CIARA (Cost Impact Analysis in Rheumatoid Arthritis patients) study in Spain aimed to assess societal costs (€2022) associated with adult patients with moderate-to-severe rheumatoid arthritis (RA) starting adva...
Observational Study
Journal of medical economics. 2026 Dec;29(1):994-1011. DOI:10.1080/13696998.2026.2644119 2026
Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors [0.03%]
整个外显子组和转录组测序与50基因检测panel在实体瘤基因组分型中的成本效益分析
Jesse D Ortendahl,Gebra Cuyun Carter,Eliza M Zantema et al.
Jesse D Ortendahl et al.
Aims: The rapid development of therapies linked to molecular biomarkers has increased the importance of next-generation sequencing (NGS)-based tumor profiling to guide treatment decisions. Technology has enabled more comp...
Global burden of disease due to young-onset dementia and the forecast for 2050: update from global burden of disease study 2021 [0.03%]
全球早发型痴呆的疾病负担及2050年的预测：来自2021年全球疾病负担研究的更新报告
Yoonseo Park,Heejae Jeong,Eun-Ji Kim et al.
Yoonseo Park et al.
Objective: The prevalence of young-onset dementia (YOD) is increasing worldwide, leading to greater economic and social burden, necessitating strategic management and prevention. ...
Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States [0.03%]
针对美国高危成人使用辉瑞-BioNTech新冠疫苗（LP.8.1分版，2025/2026季配方）的经济性、公共卫生影响及预算影响研究
Alon Yehoshua,Manuela Di Fusco,Abby E Rudolph et al.
Alon Yehoshua et al.
Objectives: To assess the cost-effectiveness, public health impact, and budget impact of receiving the LP.8.1-adapted Pfizer-BioNTech COVID-19 Vaccine among United States adults aged ≥ 18 years. ...
Trends in industry-sponsored clinical trial activity since passage of the Inflation Reduction Act [0.03%]
《通胀削减法案》通过以来行业赞助的临床试验活动趋势分析
Genia Long
Genia Long
Background and objective: By shortening the time after U.S. drug approval when substantial revenue reductions typically occur, the Inflation Reduction Act's (IRA) Drug Price Negotiation Program (DPNP) alters investment in...
Epidemiology and economic burden of medically attended influenza and influenza-like illness in Germany, 2016-2019 [0.03%]
2016-2019年德国医疗就诊的流感和类流感疾病的流行病学及经济负担
Anna C Meyer,Julian Witte,Manuel Batram et al.
Anna C Meyer et al.
Aims: Older adults and individuals with certain underlying conditions are at elevated risk of severe influenza complications. This study quantifies the burden of influenza and influenza-like illness (ILI) in Germany focus...
Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopy [0.03%]
基于模型的结直肠癌筛查效果评估：三次多目标粪便DNA检测与一次结肠镜检查的效果比较
Michael Dore,Derek W Ebner,Vahab Vahdat et al.
Michael Dore et al.
Background: Several colorectal cancer (CRC) screening modalities are guideline-recommended in the United States but differ in screening interval and real-world adherence. Accordingly, single-round test performance may not...
Estimating the public health and economic impact of increased COVID-19 annual vaccination coverage in the 60 years and older population in Spain [0.03%]
估计西班牙60岁及以上人群COVID-19年度疫苗接种覆盖率提高的公共卫生和经济影响
Santiago Moreno Guillén,Esther Redondo Margüello,Juan Rodríguez García et al.
Santiago Moreno Guillén et al.
Background: COVID-19 annual vaccination uptake in Spain remains suboptimal. This study aimed to estimate the clinical and economic impact of the 2023/2024 COVID-19 vaccination campaign in individuals aged ≥60 years (scen...
Cost-effectiveness of treatment and care of patients with gastrointestinal inflammatory diseases: a systematic review [0.03%]
胃肠炎症性疾病治疗和照护的成本效益：系统性综述
Kristina Randlová,Petra Marešová,Lukáš Režný et al.
Kristina Randlová et al.
Aims: The aim of this study was to systematically review and descriptively synthesize published cost-effectiveness evidence for biologic versus non-biologic treatments as well as comparisons among different biologic thera...